A Randomized, Blinded, Placebo-Controlled, Phase 1 Single Ascending Dose Study in Healthy Adult Male Volunteers and an Open-Label Multiple Ascending Dose Study in Pediatric SMA Participants Previously Treated With Onasemnogene Abeparvovec (Zolgensma) to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB115
Latest Information Update: 02 Jul 2025
At a glance
- Drugs BIIB 115 (Primary)
- Indications Spinal muscular atrophy
- Focus Adverse reactions; First in man
- Sponsors Biogen
Most Recent Events
- 25 Jun 2025 According to Biogen media release, Based on results from Phase 1 trial, the company is planning for Registrational trials for Spinal Muscular Atrophy.
- 25 Jun 2025 According to Biogen media release, data from this trial,presented today at the SMA Research & Clinical Care Meeting hosted by Cure SMA in Anaheim, Calif.
- 25 Jun 2025 Topline Results presented the Biogen Media Release